share_log

Cryo-Cell International (OTCMKTS:CCEL) Stock Passes Below Two Hundred Day Moving Average of $5.34

Financial News Live ·  Jan 25, 2023 15:05

Cryo-Cell International, Inc. (OTCMKTS:CCEL – Get Rating)'s share price passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $5.34 and traded as low as $4.29. Cryo-Cell International shares last traded at $4.36, with a volume of 6,392 shares.

Cryo-Cell International Stock Down 1.8 %

The stock has a market cap of $36.47 million, a price-to-earnings ratio of 28.54 and a beta of 0.30. The company's 50-day simple moving average is $4.45 and its 200-day simple moving average is $5.33.

Get Cryo-Cell International alerts:

Insiders Place Their Bets

In other news, CEO David Portnoy acquired 10,000 shares of the stock in a transaction on Monday, November 14th. The shares were purchased at an average cost of $4.80 per share, for a total transaction of $48,000.00. Following the transaction, the chief executive officer now owns 220,080 shares in the company, valued at approximately $1,056,384. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Over the last 90 days, insiders have acquired 34,366 shares of company stock worth $167,193. 33.80% of the stock is owned by insiders.

About Cryo-Cell International

(Get Rating)

Cryo-Cell International, Inc is cord blood bank, which engages in providing stem cell cryopreservation services and advancing regenerative medicine. It operates through the following segments: Cellular Processing and Cryogenic Storage, and Prepacyte CB. The Cellular Processing and Cryogenic Storage segment focuses on the collection and preservation of umbilical cord blood and tissue stem cells for family use.

See Also

  • Get a free copy of the StockNews.com research report on Cryo-Cell International (CCEL)
  • Is The Bottom In For Cyber-Security Stocks?
  • Union Pacific, Norfolk Southern Pull into Buying Zone
  • Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
  • How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
  • Is the Pain Over for Baudax Bio Investors after a 70% Spike?

Receive News & Ratings for Cryo-Cell International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryo-Cell International and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment